EU considers duplicate biologics
Executive Summary
A European Commission consultation on ‘duplicate marketing authorisations for biological medicinal products’ has been welcomed by off-patent industry association Medicines for Europe. According to the consultation – which is open until 10 September 2018 – the Commission has “identified potential issues relating to the granting of duplicate marketing authorisations for biological medicinal products on the ground that they would be a ‘first generic’”. These issues “relate to the possible impact of such duplicate marketing authorisations on the biosimilar market, including potential anti-competitive effects”.
You may also be interested in...
New EU Approach On Duplicate Marketing Authorizations Prompts Questions
The European Commission says there is no automatic link between the introduction of a duplicate marketing authorization by the holder of the original medicinal product (be it a chemical or a biological medicinal product) and the increased availability of a medicine.
New EU Approach On Duplicate Marketing Authorizations Prompts Questions
The European Commission says there is no automatic link between the introduction of a duplicate marketing authorization by the holder of the original medicinal product (be it a chemical or a biological medicinal product) and the increased availability of said medicine.
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.